MPM Capital Appoints Gregory Sieczkiewicz as Managing Director and Chief Counsel – Intellectual Property

-Experienced VC patent expert to provide IP counsel-

BOSTON--(BUSINESS WIRE)--MPM Capital today announces the appointment of Gregory Sieczkiewicz as Managing Director and Chief Counsel, Intellectual Property, effective immediately. Greg will also provide IP counsel to MPM and serve as start-up IP counsel to MPM portfolio companies. A registered patent attorney, Greg has broad experience in venture-backed creation and development of diverse IP portfolios in over a dozen start-up companies.

"Greg brings a proven track record in venture IP and, importantly, in leading the initial IP efforts of transformational life sciences firms"
"We are pleased Greg will be joining our leading and expanding life sciences team, bringing critical IP expertise and experience to MPM and our portfolio of innovative life sciences firms," said Ansbert K. Gadicke, MPM Capital Managing Director and co-founder.

"Greg brings a proven track record in venture IP and, importantly, in leading the initial IP efforts of transformational life sciences firms," Gadicke said.

Greg brings a wealth of experience accumulated over his 23-year legal and scientific career and will contribute broadly to MPM's effort to help launch and develop paradigm-breaking life science companies. Greg previously has provided in-house leadership in life sciences patent prosecution, litigation and opinion work, and has made significant contributions while at the firms Mintz Levin, Proskauer Rose and Foley Hoag. In his most recent role, Greg served as Vice President, Intellectual Property, Flagship Ventures where, among other accomplishments, Greg drove the issuance of first-in-field US patents for oral biologics and served as the IP architect and co-inventor of an industry-leading nucleic acid therapeutics patent estate. Greg has crafted the IP strategy and led the initial filing for multiple life sciences companies that are committed to changing the face of medicine across the spectrum—from the microbiome, to oncology, to protein engineering.

Prior to entering the field of patent law, Greg completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the United States Patent and Trademark Office. Greg is the President of the Boston Patent Law Association.

About MPM Capital -- MPM Capital, http://www.mpmcapital.com, is a global leader in early-stage life sciences venture investing with a track record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.

Contacts

MPM Capital
Sarah Reed, +1-781-697-4502
[email protected]
 

Suggested Articles

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.